Clinical trial · Interventional
Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer
A Phase III, Double-Blind, Randomized Study of the Effect of Megestrol Acetate on Weight and Health Related Quality of Life in Lung Cancer Patients Receiving Thoracic Radiation Therapy
NCT00031785CI-TRIAL-00053802completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Megestrol helps improve appetite. It is not yet known if megestrol is effective in limiting weight loss in patients who are undergoing radiation therapy. PURPOSE: Randomized phase III trial to determine the effectiveness of megestrol in limiting weight loss in patients who are undergoing radiation therapy for lung cancer.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anorexia | — | UNRESOLVED | — |
| Cachexia | — | UNRESOLVED | — |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| megestrol acetate | Drug | Megestrol | ALIAS |
| radiation therapy | Radiation | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 120 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed lung cancer * Unresectable stage I-IIIB non-small cell lung cancer (NSCLC) * Resected stage I-IIIB NSCLC * Limited stage small cell lung cancer * Planned radiotherapy with a total dose of at least 5,000 cGy in fraction sizes of no greater than 200 cGy each * No distant metastases * No significant ascites, pleural effusions, or edema that would inhibit oral food intake or invalidate weight determinations PATIENT CHARACTERISTICS: Age: * Over 18 Performance status: * ECOG 0-2 Life expectancy: * More than 3 months Hematopoietic: * Not specified Hepatic: * Not specified Renal: * Not specified Cardiovascular: * No uncontrolled hypertension * No active thromboembolic disease * No myocardial infarction within the past 3 months * No prior congestive heart failure or thromboembolic events Pulmonary: * No prior pulmonary edema Other: * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No other malignancy within the past 3 years except curatively treated carcinoma in situ of the cervix or non-melanoma skin cancer * No uncontrolled diabetes with glycosylated hemoglobin greater than 10% * No Cushing's syndrome * No dietary restrictions (e.g., salt, sugar, or lipid) * No other serious medical or psychiatric illness that would preclude study PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * See Endocrine therapy Endocrine therapy: * At least 12 months since prior corticosteroids, estrogens, progestins, or other steroid hormone except as antiemetic prior to chemotherapy * No concurrent corticosteroids, estrogens, progestins, or other steroid hormone except as antiemetic prior to chemotherapy Radiotherapy: * See Disease Characteristics * No prior radiotherapy to lung Surgery: * See Disease Characteristics * More than 14 days since prior surgery
References
Publications (0)
Data not yet available
No reference posted for this study.